M.S. Thesis Presentation by Todd Deterding
Thursday, April 9, 1998

(Dr. Chris Wang, advisor)

"Radiation Dosimetry of 2 b-carbomethoxy-3 b-(4-chlorophenyl)-8-(-2-fluoroethyl)nortropane ([18F]FECNT)"

Abstract

Considerable effort has been devoted recently to the development of radiolabeled biochemical probes of the dopamine transporter by positron emission tomography (PET). Changes in the amount of dopamine transporters found in the brain has been attributed to cocaine addiction, Parkinsonís disease, and schizophrenia. A radiolabeled ligand tailored specifically for observing the changes in the dopamine transport system would be a valuable technique for studying the diagnosis, treatment, and mechanisms of these afflictions.

Work on this issue at the Emory University Hospitalís Center for Positron Emission Tomography is currently focused on 2 bĖcarbomethoxy-3 b-(4-chlorophenyl)-8-(-2-fluoroethyl)nortropane ([18F]FECNT), a potent cocaine analog. Because the use of radiolabeled ligands, such as [18F]FECNT, pose a stochastic risk to human patients that is believed to be proportional to the organ-weighted effective dose, it is necessary to assess the amount of radiation absorbed dose delivered by [18F]FECNT. This thesis presents the methods and results of the estimated organ doses and the effective doses to a human administered with [18F]FECNT. The dose delivered to the basal ganglia, a brain region known to have a high density of DATs, was also estimated from PET images.